Description Usage Format References
This multi-center acute leukemia study consists of 137 patients with acute myelocytic leukemia (AML) or acute lymphoblastic leukemia (ALL) aged 7 to 52 from March 1, 1984 to June 30, 1989 at four institutions (Klein and Moeschberger, 2003). The failure time on study is defined at time (in days) to relapse or death.
1 |
The variables represented in the data set are as follows:
g
Disease group: 1 - All, 2 - AML Low Risk, 3 - AML High Risk.
T1
Time to death or on study time.
T2
Disease free survival time (time to relapse, death or end of study).
d1
Death indicator: 1 - Dead, 0 - Alive.
d2
Relapse indicator: 1 - Relapsed, 0 - Disease Free.
d3
Disease free survival indicator: 1 - Dead or Relapsed, 0 - Alive Disease Free.
TA
Time to Acute Graft-Versus-Host Disease.
da
Acute GVHD indicator: 1 - Developed Acute GVHD, 0 - Never Developed Acute GVHD.
TC
Time to Chronic Graft-Versus-Host Disease.
dc
Chronic GVHD Indicator: 1 - Developed Chronic GVHD, 0 - Never Developed Chronic GVHD.
TP
Time to return of platelets to normal levels.
dp
Platelet recovery indicator: 1 - platelets returned to normal, 0 - platelets never returned to normal.
Z1
Patient age in years.
Z2
Donor age in years.
Z3
Patient sex: 1 - Male, 0 - Female.
Z4
Doner sex: 1 - Male, 0 - Female.
Z5
Patient CMV status: 1 - CMV positive, 0 - CMV negative.
Z6
Donor CMV status: 1 - CMV positive, 0 - CMV negative.
Z7
Waiting time to transplant in days.
Z8
FAB: 1 - FAB Grade 4 or 5 and AML, 0 - otherwise.
Z9
Hospital: 1 - The Ohio State University, 2 - Alferd , 3 - St. Vincent, 4 - Hahnemann.
Z10
MTX: used as a Graft-Versus-Host-Prophylactic 1 - Yes, 0 - No.
Klein, J. P. and Moeschberger, M. L. (2003) Survival Analysis: Techniques for Censored and Truncated Data. Springer, New York, 2nd edition.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.